TLR7 Recognition is dispensable for influenza virus a infection but important for the induction of hemagglutinin-specific antibodies in response to the 2009 pandemic split vaccine in mice

Journal of Virology

Volumn 86, Issue 20, 2012, Pages 10988-10998

  Jeisy Scott, Victoria ^a,b   Kim, Jin Hyang ^a   Davis, William G ^a   Cao, Weiping ^a   Katz, Jacqueline M ^a   Sambhara, Suryaprakash ^a  

^a NATIONAL CENTER FOR IMMUNIZATION AND RESPIRATORY DISEASES   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN M ANTIBODY; INFLUENZA VACCINE; INFLUENZA VIRUS HEMAGGLUTININ; MYELOID DIFFERENTIATION FACTOR 88; TOLL LIKE RECEPTOR 7; VIRUS ANTIBODY; VIRUS RNA;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; B LYMPHOCYTE; BONE MARROW; CONTROLLED STUDY; DRUG EFFICACY; GERMINAL CENTER; HUMORAL IMMUNITY; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFLUENZA A; LYMPHOID ORGAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; VIRION;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY-PRODUCING CELLS; GERMINAL CENTER; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; IMMUNOLOGIC MEMORY; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MEMBRANE GLYCOPROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MYELOID DIFFERENTIATION FACTOR 88; ORTHOMYXOVIRIDAE INFECTIONS; RNA, VIRAL; TOLL-LIKE RECEPTOR 7;

ANIMALIA; INFLUENZAVIRUS A; MUS; ORTHOMYXOVIRIDAE;

EID: 84869044834     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01064-12     Document Type: Article

References (63)

1. Adachi O, et al. 1998. Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function. Immunity 9:143-150.
2. Ahmed R, Oldstone MB, Palese P. 2007. Protective immunity and susceptibility to infectious diseases: lessons from the 1918 influenza pandemic. Nat. Immunol. 8:1188-1193.
3. Ambrose CS, Levin MJ, Belshe RB. 2011. The relative efficacy of trivalent live attenuated and inactivated influenza vaccines in children and adults. Influenza Other Respi. Viruses 5:67-75.
4. Barchet W, et al. 2005. Dendritic cells respond to influenza virus through TLR7- and PKR-independent pathways. Eur. J. Immunol. 35:236-242.
5. Bekeredjian-Ding I, Jego G. 2009. Toll-like receptors; sentries in the B-cell response. Immunology 128:311-323.
6. Belshe RB, et al. 2007. Live attenuated versus inactivated influenza vaccine in infants and young children. N. Engl. J. Med. 356:685-696.
7. Boeglin E, et al. 2011. Toll-like receptor agonists synergize with CD40L to induce either proliferation or plasma cell differentiation of mouse B cells. PLoS One 6:e25542. doi:10.1371/journal.pone.0025542.
8. Browne EP. 2011. Toll-like receptor 7 controls the anti-retroviral germinal center response. PLoS Pathog. 7:e1002293. doi:10.1371/journal.ppat. 1002293.
9. Cao W, et al. 2011. Improving immunogenicity and effectiveness of influenza vaccine in older adults. Expert Rev. Vaccines 10:1529-1537.
10. Clingan JM, Ostrow K, Hosiawa KA, Chen ZJ, Matloubian M. 2012. Differential roles for RIG-I-like receptors and nucleic acid-sensing TLR pathways in controlling a chronic viral infection. J. Immunol. 188:4432-4440.
11. Co MD, et al. 2009. In vitro evidence that commercial influenza vaccines are not similar in their ability to activate human T cell responses. Vaccine 27:319-327.
12. Danishuddin M, Khan SN, Khan AU. 2009. Phylogenetic analysis of surface proteins of novel H1N1 virus isolated from 2009 pandemic. Bioinformation 4:94-97.
13. Diamond MS, et al. 2003. A critical role for induced IgM in the protection against West Nile virus infection. J. Exp. Med. 198:1853-1862.
14. Doherty PC, Turner SJ, Webby RG, Thomas PG. 2006. Influenza and the challenge for immunology. Nat. Immunol. 7:449-455.
15. Fichera E, Felnerova D, Mischler R, Viret JF, Glueck R. 2009. New strategies to overcome the drawbacks of currently available flu vaccines. Adv. Exp. Med. Biol. 655:243-252.
16. Fink K, et al. 2006. Early type I interferon-mediated signals on B cells specifically enhance antiviral humoral responses. Eur. J. Immunol. 36: 2094-2105.
17. Fotin-Mleczek M, et al. 2011. Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity. J. Immunother. 34:1-15.
18. Geeraedts F, et al. 2008. Superior immunogenicity of inactivated whole virus H5N1 influenza vaccine is primarily controlled by Toll-like receptor signalling. PLoS Pathog. 4:e1000138. doi:10.1371/journal.ppat.1000138.
19. Glaum MC, et al. 2009. Toll-like receptor 7-induced naive human B-cell differentiation and immunoglobulin production. J. Allergy Clin. Immunol. 123:224-230.e4.
20. Hall TA. 1999. BioEdit: a user-friendly biological sequence alignment editor and analysis program for Windows 95/98/NT. Nucleic Acids Symp. Ser. 41:95-98.
21. Hanten JA, et al. 2008. Comparison of human B cell activation by TLR7 and TLR9 agonists. BMC Immunol. 9:39. doi:10.1186/1471-2172-9-39.
22. Heer AK, et al. 2007. TLR signaling fine-tunes anti-influenza B cell responses without regulating effector T cell responses. J. Immunol. 178: 2182-2191.
23. Hickling J, D'Hondt E. 2006. A review of production technologies for influenza virus vaccines, and their suitability for deployment in developing countries for influenza pandemic preparedness. World Health Organization, Geneva, Switzerland.
24. Hou B, et al. 2011. Selective utilization of Toll-like receptor and MyD88 signaling in B cells for enhancement of the antiviral germinal center response. Immunity 34:375-384.
25. Ichinohe T, Lee HK, Ogura Y, Flavell R, Iwasaki A. 2009. Inflammasome recognition of influenza virus is essential for adaptive immune responses. J. Exp. Med. 206:79-87.
26. Itoh Y, et al. 2009. In vitro and in vivo characterization of new swineorigin H1N1 influenza viruses. Nature 460:1021-1025.
27. Jeisy-Scott V, et al. 2011. Increased MDSC accumulation and Th2 biased response to influenza A virus infection in the absence of TLR7 in mice. PLoS One 6:e25242. doi:10.1371/journal.pone.0025242.
28. Kang SM, et al. 2011. MyD88 plays an essential role in inducing B cells capable of differentiating into antibody-secreting cells after vaccination. J. Virol. 85:11391-11400.
29. Kastenmuller K, et al. 2011. Protective T cell immunity in mice following protein-TLR7/8 agonist-conjugate immunization requires aggregation, type I IFN, and multiple DC subsets. J. Clin. Invest. 121:1782-1796.
30. Kasturi SP, et al. 2011. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470:543-547.
31. Kawai T, Akira S. 2006. TLR signaling. Cell Death Differ. 13:816-825.
32. Kilpinen S, Hurme M. 1998. Low CD3_CD28-induced interleukin-2 production correlates with decreased reactive oxygen intermediate formation in neonatal T cells. Immunology 94:167-172.
33. Kopf M, Brombacher F, Bachmann MF. 2002. Role of IgM antibodies versus B cells in influenza virus-specific immunity. Eur. J. Immunol. 32: 2229-2236.
34. Koyama S, et al. 2010. Plasmacytoid dendritic cells delineate immunogenicity of influenza vaccine subtypes. Sci. Transl. Med. 2:25ra24. doi10.1126/scitranslmed.3000759.
35. Koyama S, et al. 2007. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J. Immunol. 179:4711-4720.
36. Lakadamyali M, Rust MJ, Zhuang X. 2004. Endocytosis of influenza viruses. Microbes Infect. 6:929-936.
37. Lanzavecchia A, Sallusto F. 2007. Toll-like receptors and innate immunity in B-cell activation and antibody responses. Curr. Opin. Immunol. 19:268-274.
38. Lopez CB, et al. 2004. TLR-independent induction of dendritic cell maturation and adaptive immunity by negative-strand RNA viruses. J. Immunol. 173:6882-6889.
39. Lorenzi JC, et al. 2010. Intranasal vaccination with messenger RNA as a new approach in gene therapy: use against tuberculosis. BMC Biotechnol. 10:77. doi:10.1186/1472-6750-10-77.
40. Lund JM, et al. 2004. Recognition of single-stranded RNA viruses by Toll-like receptor 7. Proc. Natl. Acad. Sci. U. S. A. 101:5598-5603.
41. Meyer-Bahlburg A, Khim S, Rawlings DJ. 2007. B cell intrinsic TLR signals amplify but are not required for humoral immunity. J. Exp. Med. 204:3095-3101.
42. Neumann G, Kawaoka Y. 2011. The first influenza pandemic of the new millennium. Influenza Other Respi. Viruses 5:157-166.
43. Ochsenbein AF, et al. 1999. Control of early viral and bacterial distribution and disease by natural antibodies. Science 286:2156-2159.
44. Palese P. 2006. Making better influenza virus vaccines? Emerg. Infect. Dis. 12:61-65.
45. Pang IK, Iwasaki A. 2011. Inflammasomes as mediators of immunity against influenza virus. Trends Immunol. 32:34-41.
46. Pape KA, Taylor JJ, Maul RW, Gearhart PJ, Jenkins MK. 2011. Different B cell populations mediate early and late memory during an endogenous immune response. Science 331:1203-1207.
47. Pasare C, Medzhitov R. 2005. Control of B-cell responses by Toll-like receptors. Nature 438:364-368.
48. Reed, L. J., andH. Muench. 1938. A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27:493-497.
49. Reed C, et al. 2009. Estimates of the prevalence of pandemic (H1N1) 2009, United States, April-July 2009. Emerg. Infect. Dis. 15:2004-2007.
50. Ruprecht CR, Lanzavecchia A. 2006. Toll-like receptor stimulation as a third signal required for activation of human naive B cells. Eur. J. Immunol. 36:810-816.
51. Sambhara S, et al. 2001. Heterosubtypic immunity against human influenza A viruses, including recently emerged avian H5 and H9 viruses, induced by FLU-ISCOM vaccine in mice requires both cytotoxic T-lymphocyte and macrophage function. Cell. Immunol. 211:143-153.
52. Seo S-U, et al. 2010. MyD88 signaling is indispensable for primary influenza A virus infection but dispensable for secondary infection. J. Virol. 84:12713-12722.
53. Shukla NM, et al. 2011. Toward self-adjuvanting subunit vaccines: model peptide and protein antigens incorporating covalently bound Toll-like receptor-7 agonistic imidazoquinolines. Bioorg. Med. Chem. Lett. 21: 3232-3236.
54. Szretter KJ, Balish AL, Katz JM. 2006. Influenza: propagation, quantification, and storage. Curr. Protoc. Microbiol. Chapter 15:Unit 15G.1.
55. Takeda K, Akira S. 2004. TLR signaling pathways. Semin. Immunol. 16:3-9.
56. Taubenberger JK. 2006. The origin and virulence of the 1918 "Spanish" influenza virus. Proc. Am. Philos. Soc. 150:86-112.
57. Tsukamoto Y, et al. 2009. Toll-like receptor 7 cooperates with IL-4 in activated B cells through antigen receptor or CD38 and induces class switch recombination and IgG1 production. Mol. Immunol. 46:1278-1288.
58. Vesikari T, et al. 2011. Oil-in-water emulsion adjuvant with influenza vaccine in young children. N. Engl. J. Med. 365:1406-1416.
59. Vukmanovic-Stejic M, Vyas B, Gorak-Stolinska P, Noble A, Kemeny DM. 2000. Human Tc1 and Tc2/Tc0 CD8 T-cell clones display distinct cell surface and functional phenotypes. Blood 95:231-240.
60. Wei J, et al. 2010. Influenza A infection enhances cross-priming of CD8_ T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion. J. Immunol. 185:6013-6022.
61. WHO. 2009. 2009. Influenza (seasonal) fact sheet. WHO, Geneva, Switzerland.
62. Wille-Reece U, Wu CY, Flynn BJ, Kedl RM, Seder RA. 2005. Immunization with HIV-1 Gag protein conjugated to a TLR7/8 agonist results in the generation of HIV-1 Gag-specific Th1 and CD8_ T cell responses. J. Immunol. 174:7676-7683.
63. Zhou ZH, Tzioufas AG, Notkins AL. 2007. Properties and function of polyreactive antibodies and polyreactive antigen-binding B cells. J. Autoimmun. 29:219-228.